- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01162109
Zinc Therapy in Critical Illness
Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis
Sepsis is a clinical syndrome often caused by a bloodstream infection that results in a common set of symptoms termed systemic inflammatory response syndrome (SIRS). Severe sepsis (sepsis with organ failure) is the leading cause of death in critically ill patients in the US. Most patients with severe sepsis need to be treated in the intensive care unit with mechanical ventilation and intravenous antibiotics. Between 30 to 50% of all severe sepsis patients die and quality of life in survivors is substantially reduced. New therapies are needed to improve clinical outcomes in patients with sepsis.
A new area of interest in the treatment of critical illness is pharmaconutrition, in which micronutrients (like zinc) are studied and administered to determine if they affect the inflammatory response or immunologic processes in critical illness. The FDA does not regulate micronutrients and does not require rigorous pharmacokinetic (the study of how a drug or nutrient is metabolized in the body) testing so it is not clear how to dose micronutrients in critically ill patients. It is also not clear if critically ill patients would metabolize these micronutrients differently than healthy people and would need different dosing levels. This is true of zinc, the focus of this research study.
Zinc is essential for normal immune function, oxidative stress response, and wound healing, and its homeostasis is tightly regulated. Zinc deficiency occurs in >10% of Americans and leads to loss of innate and adaptive immunity and increased susceptibility to infections. The symptoms of zinc deficiency are similar to many of the symptoms of SIRS and there is strong biologic rationale to suggest that the zinc deficiency seen in nearly all sepsis patients may contribute to the development of sepsis syndrome and to the "immunoparalysis" common in sepsis patients
This study has three specific aims, 1) to perform a phase I dose-finding study of intravenous zinc in mechanically ventilated patients with severe sepsis; 2) to define the pharmacokinetic of intravenous zinc in mechanically ventilated patients with severe sepsis compared to healthy controls; and 3) to investigate the impact of zinc on inflammation, immunity, and oxidant defense in patients with severe sepsis.
A total of 40 critically ill patients from the FAHC intensive care units and 15 healthy controls will be enrolled in the study. The critically ill patient population will be divided into 4 dosing groups of 10 subjects (7 randomized to zinc and 3 to saline placebo). Group 1 will receive 500mcg/kg IBW/day elemental zinc in divided doses every 8 hours. If the 50th percentile of the normal plasma zinc range (110mcg/dL) has not been achieved in all patients by 7 days and there are no safety concerns, sequential groups of patients will receive increasing doses in 250mcg increments to the ceiling dose. Groups 2 through 4 will receive 750, 1000, and 1250mcg/kgIBW/day elemental zinc, respectively. Each participant will receive the intravenous zinc or placebo for a total of 7 days unless they die or leave the ICU earlier. Pharmacokinetic testing will be obtained from 40 of the critically ill subjects and in 15 healthy controls. Additional blood will be drawn during the infusion protocol to investigate the impact of zinc on inflammation, immunity, and oxidant defense.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe sepsis
- Requiring mechanical ventilation
- 18 years or older
Exclusion Criteria:
- >36 hours since meeting severe sepsis criteria4
- Expected ICU length of stay <72 hours
- Pre-existing gastrointestinal disease*
- Post-cardiac arrest with significant anoxic brain injury
- Creatinine clearance <40mL/min*
- Taking zinc supplement during past month*
- Has received zinc supplementation while hospitalized
- Pregnant or lactating*
- AIDS with CD4<200*
- Previous bone marrow or solid organ transplant*
- Receiving TPN with added zinc
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Severe sepsis without zinc
Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
|
A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops. A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis. |
Experimental: Zinc in severe sepsis
Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
|
A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops. A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis. |
Experimental: Healthy Volunteers receiving zinc
Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours.
PK in sepsis patients and healthy volunteers will be compared.
|
A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops. A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics/pharmacodynamics
Time Frame: Several time points over one week during critical illness
|
Several time points over one week during critical illness
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Production of TNF-alpha by circulating monocytes
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Production of IL-1beta by circulating monocytes
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Production of IL-6 by circulating monocytes
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Production of IL-8 by circulating monocytes
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Plasma TNF-alpha
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Plasma IL-1beta
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Plasma IL-6
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Plasma IL-8
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Serum malondialdehyde (MDA)
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Serum 8-hydroxydeoxyguanine (8-OHdG)
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Neutrophil phagocytosis
Time Frame: Study days 1, 3, and 7
|
Study days 1, 3, and 7
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Renee D Stapleton, MD, PhD, University of Vermont
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Zinc1017
- 1K23HL105654 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Sepsis
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Rennes University HospitalUnknownSevere Sepsis or Septic Shock
-
Beckman Coulter, Inc.CompletedSepsis | Severe Sepsis | Severe InfectionFrance, Spain
-
Yonsei UniversityCompletedSevere Sepsis or Septic ShockKorea, Republic of
-
University of RostockCompletedSevere Sepsis and Septic ShockGermany
-
Centre Hospitalier Universitaire de NiceUnknownComparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis. (PREDI)Severe Sepsis and Septic ShockFrance
-
University Hospital, Strasbourg, FranceUnknownSevere Sepsis and Septic ShockFrance
-
Peking Union Medical College HospitalUnknownLactate | Severe Sepsis With Septic Shock
-
University of UtahNational Institutes of Health (NIH)CompletedSevere Sepsis With Septic Shock
Clinical Trials on Zinc sulfate
-
International Centre for Diarrhoeal Disease Research...Completed
-
Instituto Nacional de Salud Publica, MexicoUNICEFCompletedDiarrhea, Infantile | Diarrhoea;AcuteMexico
-
Hormozgan University of Medical SciencesCompleted
-
Babylon UniversityMinistry of Health, IraqCompletedAsthenozoospermiaIraq
-
mahmoud hussein hadwanMinistry of Health, IraqCompleted
-
Mansoura UniversityCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedGastric Carcinoma | Unresectable Pancreatic Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Esophageal CarcinomaUnited States
-
Universidad Nacional Autonoma de MexicoHospital General de Mexico; Hospital Pediatrico de CoyoacanCompletedPneumonia | Children, OnlyMexico
-
UCSF Benioff Children's Hospital OaklandChildren's Hospital Medical Center, CincinnatiCompletedCritical IllnessUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Radiation Toxicity | Dysgeusia | Oral Complications